Tag - CPH

Markets

Mackie Research cuts Cipher Pharma to hold; PT to $1 (Canadian) from $1.50

Mackie Research Capital downgraded Cipher Pharmaceuticals (TSX:CPH) to “hold” from “buy” and reduced its price target to $1 (Canadian) from $1.50, citing marketing uncertainty, partially due to a recent unfavorable...

January 25, 2021

Markets

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie Research lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $1 (Canadian) from $2.30, citing a delay in the out-licensing of its Canadian assets because of a dispute with Bausch Health (NYSE:BHC)...

March 27, 2020

Markets

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

Mackie Research Capital lowered its price target for Cipher Pharmaceuticals (TSX:CPH) to $5.30 from $7.10 after the company lowered first quarter expectations on the back of weak Absorica sales. Analyst Andre Uddin...

April 24, 2018

Tag - CPH

Mackie Research cuts Cipher Pharma to hold; PT to $1 (Canadian) from $1.50

Mackie cuts Cipher Pharma PT to $1 from $2.30

Mackie cuts Cipher Pharma PT to $5.30 from $7.10

General

More